Business & Industry
Asia’s CROs VCs: Blurring Service Provider & Investor Roles
In a time characterized by accelerated innovation and ever-more complicated clinical environments, Asia is witnessing an invigorating shift in the role of Contract Research Organizations (CROs). Once seen as service organizations that assist in the pharmaceutical and biotech product...
Clinical Trials
How To Select A CDMO: Focus On Client-Centered Approach
When it comes to the pharmaceutical sector, choosing the correct contract development and manufacturing organization (CDMO) is essential to having a successful trip through the process of making a pharmaceutical product. This choice is dependent on two crucial aspects:...
Clinical Trials
FDA Approval of AMVUTTRA for ATTR Amyloidosis
Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics, has announced U.S. FDA approval of AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. This approval makes AMVUTTRA the first and...
Clinical Trials
Rina-S Shows Promise in Advanced Ovarian Cancer
Genmab has reported encouraging findings from the Phase 2 RAINFOL-01 trial of rinatabart sesutecan (Rina-S®), an experimental folate receptor-alpha (FRα)-targeted, TOPO1 antibody-drug combination (ADC). Data from the B1 cohort of the trial showed encouraging antitumor efficacy in highly pre-treated...
Clinical Trials
Artificial Intelligence – Giving Clinical Trial A Facelift
Across the past so many years, there have been pharmaceutical companies that have been integrating artificial intelligence steadily into many elements of clinical development. The effect that artificial intelligence has today is indeed being felt right from the bench...
Clinical Trials
New Data Shows Gazyva’s Superiority in Lupus Nephritis
The New England Journal of Medicine has published detailed findings from Roche’s Phase III REGENCY trial, which demonstrated the superiority of Gazyva®/Gazyvaro® (obinutuzumab) in combination with standard therapy for treating active lupus nephritis (LN). The trial shows a compelling...
Clinical Trials
EYLEA HD® Phase 3 Trial Yields Promising Results
Regeneron Pharmaceuticals, Inc. announced promising results from the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg for treating macular edema in patients with retinal vein occlusion (RVO). The results were presented during the Angiogenesis 2025 annual...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read